September 24, 2025 - NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS
Submitted by wim@als.be on Mon, 11/24/2025 - 16:53Louise Gunning-Schepers
I am the co-chair of the Patient Advisory Board of ALS Patients Association (The Netherlands), which is active in advising the board among others on research applications that we review from a patient perspective.
Today (2025), I am 74 years old and have been diagnosed with PLS, almost four years ago. During my career I was an epidemiologist and a professor in Social Medicine. I was dean of medicine at the University of Amsterdam. I have sat on many committees at the national and EU level that have reviewed research proposals.
Image:
Valérie Berlaimont
Two years ago, I have been diagnosed with familial ALS (TARDBP gene mutation) after experiencing symptoms since summer 2021. Today (2025), I am 57 and I almost entirely lost upper limb function. I am well supported by my husband and two adult children. I have a passion for travel and singing.
After more than 20 years as scientist in the pharmaceutical industry, I’m honored and happy to join the EUpALS PCEB as pALS where I will find a new sense of purpose.
Image:
